Company news

Iambic Therapeutics, Inc. news

Latest news releases, newest first.

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers

October 26, 2026